Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Plans $30M Placement as Q4 Revenues Fall and Loss Widens

NEW YORK, March 28 (GenomeWeb News) - Sequenom today posted declining revenues and a widened loss for the fourth quarter of 2005.


Separately, the company said that it plans to issue more than 54.5 million shares of common stock and around 32.7 million purchase warrants at $0.70 per share to raise $30 million by May 31.


For the quarter ended Dec. 31, 2005, Sequenom revenues fell 28 percent to $4.4 million from $6.1 million in the fourth quarter of 2004.


The company's net loss increased to $7.0 million, or $.17 per share, from $6.6 million, or $.16 per share, in the year-ago period.


Sequenom spent $3.0 million on research and development in the fourth quarter, down 23 percent from $3.9 million in the fourth quarter of 2004.


As of Dec. 31, the company had $8.7 million in cash, cash equivalents, short-term investments and restricted cash.


Harry Stylli, president and CEO of Sequenom, said in a statement that the restructuring activities that the company announced in September "will positively impact 2006."


He added that the company's recently launched iPLEX multiplexing assay and MassARRAY Compact system will be "the primary contributor[s] to top line revenue growth in 2006."


Sequenom projected 2006 revenues of $24 million - a 24 percent increase over 2005 revenues of $19.4 million. The company also expects to reduce its cash use by $10 million in 2006.


The company said it plans to complete development of a proprietary fetal DNA enrichment method in the third quarter, and to launch its iPLEX II system in the fourth quarter.


Sequenom added that it expects to launch a research-use only prenatal diagnostic for Rhesus D "in early 2007," and that it plans to "establish relationships with CLIA-certified laboratories" prior to the launch.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.